Grantham, Mayo, Van Otterloo & Co (GMO)
MRNA icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Moderna MRNA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-255,018
Closed -$7.04M – 640
2025
Q2 		$7.04M Sell
255,018
-508,235
-67% -$13.4M 0.02% 261
2025
Q1 		$21.6M Buy
763,253
+215,441
+39% +$7.65M 0.07% 178
2024
Q4 		$22.8M Buy
+547,812
New +$26.2M 0.07% 178
2024
Q2 		– Sell
-306,480
Closed -$32.7M – 563
2024
Q1 		$32.7M Sell
306,480
-105,366
-26% -$10.6M 0.12% 124
2023
Q4 		$41M Buy
411,846
+105,431
+34% +$8.87M 0.18% 102
2023
Q3 		$31.6M Buy
306,415
+51,474
+20% +$5.74M 0.15% 127
2023
Q2 		$31M Buy
254,941
+103,141
+68% +$13.8M 0.14% 130
2023
Q1 		$23.3M Buy
+151,800
New +$25M 0.12% 167

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s MRNA Position: Q3 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Moderna (MRNA) in Q3 2025, closing a stake of 255,018 shares — an estimated $7.04M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in MRNA in Q1 2023 and held it in 8 quarters. The position peaked at $41M in Q4 2023. 646 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 255,018 Moderna shares in Q3 2025, an estimated $7.04M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Moderna in Q1 2023 and held it in 8 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Moderna position peaked at $41M in Q4 2023.
  • 646 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2025, filed 13 Nov 2025.